Printer Friendly

BELMAC GRANTED UNITED STATES PATENT FOR ANTI-MALARIAL DRUGS

    TAMPA, Fla., Oct. 27 /PRNewswire/ -- Belmac Corporation (AMEX: BLM) announced today that it was granted United States Patent 5,250,734 on Oct. 5, 1993 covering several of its new lead compounds in the Phenantramine series of anti-malarial agents.  Pre-clinical tests have shown these compounds to posses significant activity against drug- sensitive and -resistant strains of malaria.  The new compounds are the first to be synthesized and patented by Belmac chemists.
    "This patent is a significant milestone in the development of Phenantramine and demonstrates Belmac's continuous research programs to develop novel, active drugs", commented Michael Randazzo, Ph.D., Belmac's chief medicinal chemist.
    Belmac Corporation is an international pharmaceutical and health care corporation based in Tampa.
    -0-             10/27/93
    CONTACT:  Jill Figueredo, or R. Stewart of Belmac, 813-286-4401
    (BLM) CO:  BELMAC CORPORATION IN:  MTC ST:  FL


-- FL003 -- X398 10/27/93
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 27, 1993
Words:141
Previous Article:WICOR CEO STUART TISDALE ANNOUNCES RETIREMENT PLANS
Next Article:CELOX CORPORATION HIRES SALES MANAGER
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters